LVTX
Price:
$1.6
Market Cap:
$42.07M
LAVA Therapeutics N.V., a clinical-stage immuno-oncology company, focuses on developing cancer treatments. The company, through its Gammabody platform, develops a portfolio of novel bispecific antibodies to engage and leverage the potency and precision of gamma delta T cells to elicit an anti-tumor immune response and enhance outcomes for cancer patients. Its lead clinical-stage candidates are LAVA-051, which is in Phase 1/2a clinical trial for blood cancers, including chronic lymphocytic leukemia, multiple myeloma, and acute myeloid leukemia; and LAVA-1207 that is in Phase 1/2a clinical trial for metastatic castration-resistant prostate cancer. The company is also developing other Gammabody...[Read more]
Industry
Biotechnology
IPO Date
2021-03-26
Stock Exchange
NASDAQ
Ticker
LVTX
According to LAVA Therapeutics N.V.’s latest financial reports and current stock price. The company's current PE Ratio is -1.80. This represents a change of -84.02% compared to the average of -11.26 of the last 4 quarters.
The mean historical PE Ratio of LAVA Therapeutics N.V. over the last ten years is -11.27. The current -1.80 PE Ratio has changed 1.50% with respect to the historical average. Over the past ten years (40 quarters), LVTX's PE Ratio was at its highest in in the September 2022 quarter at 31.55. The PE Ratio was at its lowest in in the March 2024 quarter at -40.82.
Average
-11.27
Median
-2.84
Minimum
-27.18
Maximum
-1.01
Discovering the peaks and valleys of LAVA Therapeutics N.V. PE Ratio, unveiling quarterly and yearly fluctuations to gain insights into the company’s financial performance and market dynamics, offering valuable data for investors and analysts alike.
Maximum Annual Increase = 10.84%
Maximum Annual PE Ratio = -1.01
Minimum Annual Increase = -88.73%
Minimum Annual PE Ratio = -27.18
Year | PE Ratio | Change |
---|---|---|
2023 | -1.01 | -64.61% |
2022 | -2.84 | 10.84% |
2021 | -2.57 | -88.73% |
2020 | -22.76 | -16.26% |
The current PE Ratio of LAVA Therapeutics N.V. (LVTX) is greater than its 3-year, greater than its 5-year, and greater than its 10-year historical averages
3-year avg
-2.14
5-year avg
-11.27
10-year avg
-11.27
LAVA Therapeutics N.V.’s PE Ratio is greater than Anebulo Pharmaceuticals, Inc. (-4.78), less than PMV Pharmaceuticals, Inc. (-1.61), greater than Miromatrix Medical Inc. (-7.13), greater than ZIVO Bioscience, Inc. (-5.20), less than Bionomics Limited (-0.22), greater than Edgewise Therapeutics, Inc. (-24.30), less than Ikena Oncology, Inc. (-1.38), greater than Design Therapeutics, Inc. (-6.66), less than Xilio Therapeutics, Inc. (-0.90), greater than Eliem Therapeutics, Inc. (-2.42), less than Aerovate Therapeutics, Inc. (-0.91), greater than Adagene Inc. (-3.02), greater than Acrivon Therapeutics, Inc. Common Stock (-3.24), greater than Rezolute, Inc. (-4.94), less than AN2 Therapeutics, Inc. (-0.66), less than Generation Bio Co. (-0.63), less than Kronos Bio, Inc. (-0.64), greater than Erasca, Inc. (-4.79), greater than C4 Therapeutics, Inc. (-2.80), greater than Neoleukin Therapeutics, Inc. (-5.86), greater than Instil Bio, Inc. (-2.26), less than Achilles Therapeutics plc (-0.64), less than NextCure, Inc. (-0.57), greater than Assembly Biosciences, Inc. (-2.34),
Company | PE Ratio | Market cap |
---|---|---|
-4.78 | $37.86M | |
-1.61 | $83.31M | |
-7.13 | $92.95M | |
-5.20 | $74.08M | |
-0.22 | $5.75M | |
-24.30 | $3.05B | |
-1.38 | $82.52M | |
-6.66 | $318.21M | |
-0.90 | $39.21M | |
-2.42 | $342.68M | |
-0.91 | $76.81M | |
-3.02 | $97.11M | |
-3.24 | $202.87M | |
-4.94 | $284.50M | |
-0.66 | $39.99M | |
-0.63 | $91.51M | |
-0.64 | $54.49M | |
-4.79 | $763.36M | |
-2.80 | $300.00M | |
-5.86 | $8.20M | |
-2.26 | $170.65M | |
-0.64 | $43.57M | |
-0.57 | $33.33M | |
-2.34 | $95.60M |
One of the best ways to find valuable stocks to invest in is to build a custom made screener in your Excel or Google Sheets spreadsheet. This allows you to compare thousands of companies like LAVA Therapeutics N.V. using the financials and key metrics that matter to you in a single view.
The easiest way to set this up is to use the Wisesheets add-on and set your spreadsheet like this:
Covering all these metrics from financial, data, dividend data, key metrics and more you can get all the data you want for over 50+ exchanges worldwide.
Get your free trial here.
The easiest way to analyze a company like LAVA Therapeutics N.V. or any others is to create a spreadsheet model that automatically retrieves all of the stock data you need.
Using Wisesheets you can set up a spreadsheet model like this with simple spreadsheet formulas. If you change the ticker you can get all of the data automatically updated for you.
Whether you need live data, historical price data, financials, dividend data, key metrics, analyst estimates, or anything else...Wisesheets has you covered.
What is the PE Ratio?
How can you use the PE Ratio?
What is LAVA Therapeutics N.V.'s PE Ratio?
How is the PE Ratio calculated for LAVA Therapeutics N.V. (LVTX)?
What is the highest PE Ratio for LAVA Therapeutics N.V. (LVTX)?
What is the 3-year average PE Ratio for LAVA Therapeutics N.V. (LVTX)?
What is the 5-year average PE Ratio for LAVA Therapeutics N.V. (LVTX)?
How does the current PE Ratio for LAVA Therapeutics N.V. (LVTX) compare to its historical average?